Direct healthcare professional communications (DHPC)
Artrodar®50mg (diacerein): New restrictions of use to limit the risk of severe diarrhoea and effects on the liver
Written by kobu · 12 February 2015
Date: 12 February 2015
Description:
A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the risk of severe diarrhoea and hepatotoxicity with the osteoarthritis medication, Artrodar® (diacerein). The use has been restricted to minimise these risks, including tightening of indication and recommending a lower starting dose.The package inserts for Artrodar® will be updated by TRB Chemedica Malaysia Sdn. Bhd.to reflect these safety changes. Please refer to the DHPC for further information.